Premium
Long‐term treatment with deferiprone in a L1 veteran
Author(s) -
Meo Anna,
Ruggeri Annalisa,
Rosa Maria Angela La,
Zanghì Laura,
Kordes Uwe,
Fischer Roland
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2005.00413.x
Subject(s) - deferiprone , medicine , deferoxamine , liver function , deferasirox , gastroenterology , chelation therapy , hepatitis c virus , liver function tests , serum ferritin , ferritin , thalassemia , pediatrics , virus , immunology
We studied a patient with mild β ‐thalassaemia major under treatment with the oral chelator deferiprone (DFP or L1) for about 10 yr (L1 veteran). Due to poor compliance with desferrioxamine, the patient started compassionate use of DFP at an age of 23 yr with a serum ferritin of 5200 μ g/L. Monitoring iron overload by SQUID biosusceptometry revealed a dramatic decrease of liver iron concentrations from 4500 to 950 μ g/g liver within 9.5 yr. A good clinical response to chelation treatment with DFP was observed together with an improvement of liver and cardiac function and a reduction in the hepatitis virus load.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom